Dietary restriction

Studies of Dietary restriction in people

539 studies gave Dietary restriction to people and measured what changed

What changedDesignPeopleSource

down: Decreases TNF-alpha

down: Decreases malondialdehyde

Randomized trial12 weeks60 peopleadultsObesityMetabolites, Nov 12, 2026

down: Decreases total and regional fat mass

down: Decreases fasting insulin

Trial12 weeks26 peopleWomen42.9 ± 5.9 years, range: 32.7–54.5 yearsMidlife adults; overweight or obesityFrontiers in nutrition, Nov 12, 2026

down: Decreases visceral fat volumeVisceral fat: 15.0% versus approximately 9.1% reduction; subcutaneous fat: 18.6% versus approximately 9.2% reduction

Randomized trial6 weeks20 peopleBothmiddle-agedMidlife adultsLasers in medical science, Nov 4, 2026

up: Increases AGP1 N-glycan branching and fucosylation

Trial24 months26 peopleadultsNon-obese adultsmedRxiv, Nov 2, 2026

down: Decreases kynurenine

up: Increases exercise-induced kynurenic acid response

Trial12 weeks21 peopleWomenolderOlder adults; resting concentrationsJournal of translational medicine, Nov 2, 2026

down: Decreases body weight

Randomized trial12 weeks60 peopleMenSedentary men with overweight or obesityObesity pillars, Nov 1, 2026

down: Decreases body weight-2.7 kg (95% CI -2.9 to -2.4)

down: Decreases blood pressure

down: Decreases mean glucose

Randomized trial4 weeks68 peopleWomenadultsAcross the 16:8 and 5:2 groups with overweight or obesityObesity (Silver Spring, Md.), Oct 28, 2026

no change: Has no effect on intrahepatic fat fraction−0.4 percentage points versus usual care; 95% CI −2.0 to 1.2; P = 0.93

Randomized trial12 weeks187 peopleBothadultsObesityNature communications, Oct 14, 2026

up: Improves metabolic parametersmean weight loss of ≈10%

down: Decreases oxidative stress and ROS signaling

down: Decreases NLRP3 expression

Trial24-week45 people33 females (73.3%) and 12 males (26.7%)mean age of 46.2 ± 8.7 yearsAdults with obesityiScience, Oct 5, 2026

down: Decreases body weight

down: Decreases HOMA-IR

down: Decreases C-reactive protein

Trial20 weeks36 peoplewomenbetween 19 and 40 yearsWomen with polycystic ovary syndrome and insulin resistanceResearch Square, Oct 4, 2026

down: Decreases body weightDiC − 3·36 kg, 95 % CI − 5·84 to −0·87

down: Decreases fat massDiC − 1·53 kg, −2·86 to −0·19

down: Decreases visceral fat areaDiC − 12·82 cm, −20·16 to −5·48

Randomized trial7 weeks131 peoplewomenaged 18–45 yearsWomen aged 18–45 years with a BMI ≥ 27 kg/m and the ability to walk on a treadmill or ride a bicycle for at least 60 minThe British journal of nutrition, Sep 25, 2026

down: Decreases body weight-3.50 kg ± 2.9

no change: Has no effect on thyroid function

Randomized trial6 weeks39 people35.9% malemean age 56.3 yearsParticipants with previously diagnosed T2DM, body mass index (BMI) ≥ 25 kg/m2, and hemoglobin A1c between 5.5% and 9.0%Journal of the Endocrine Society, Sep 23, 2026

down: Decreases body weightWMD −1.64 kg, 95% CI −2.49 to −0.79

down: Decreases fat massWMD −1.30 kg, 95% CI −1.72 to −0.89

down: Decreases waist circumferenceWMD −1.53 cm, 95% CI −2.61 to −0.44

Review of trials602 people pooledPatient cohortsNutrition reviews, Sep 15, 2026

down: Decreases total cholesterol

down: Decreases triglyceride

Randomized trial12 weeks24 peoplePatient cohortsResearch Square, Sep 10, 2026

down: Decreases body weight−6.83 ± 4.26 kg (−7.02%)

down: Decreases body fat mass−5.38 ± 3.13 kg (−13.61%)

down: Decreases soft lean mass−1.44 ± 1.88 kg (−2.68%)

Trial62-day35 people20 males (57.10%) and 15 females (42.90%)average age of 36.23 ± 8.98 yearsIndividuals with obesity in ChinaFrontiers in nutrition, Sep 9, 2026

down: Decreases glucose-7 ± 3 mg/dL

down: Decreases HbA1c-0.2 ± 0.1%

up: Improves glycemic control+3.2 ± 1.6%

Trial6-week15 peoplemean age of 62 ± 9 yearsIn veterans with spinal cord injury and obesityNutrients, Aug 29, 2026

down: Decreases predicted 10-year MACE risk−0.2 pp, p < 0.001

down: Decreases predicted 10-year type 2 diabetes risk−5.2 pp, p < 0.001

Randomized trial1 year221 peoplepremenopausal women21-49 yearsPremenopausal women with overweightObesity (Silver Spring, Md.), Aug 23, 2026

no change: Has no effect on thigh muscle area

no change: Has no effect on intermuscular adipose tissue

Randomized triala month-long66 peopleGeneral populationClinical radiology, Aug 22, 2026

down: Decreases body mass

Randomized trial4 weeks80 peopleMenyoung adultAlternate-day fasting protocolPreprints.org, Aug 19, 2026

no change: Has no effect on cumulative live birthaRR 0.936; 95% CI 0.676–1.295; P = 0.689

Randomized trial273 peopleWomen20–38 yearsWomen with overweight or obesity planning IVFReproductive biology and endocrinology : RB&E, Aug 19, 2026

up: Increases time in range92.4 ± 5% versus 81.4 ± 6.5%; p = 0.001

Randomized trial51 people25–55 yearsMidlife adults; Type 2 diabetes of ≤5 yearsDiabetology & metabolic syndrome, Aug 13, 2026

down: Decreases eating window9.2 ± 1.4 h vs 13.3 ± 1.5 h

no change: Has no effect on frailtyp > 0.05

no change: Has no effect on fatiguep > 0.05

Randomized trial12 weeks24 peopleBoth68.8 ± 6.4 yearsOlder adults; cancer receiving systemic therapyJournal of geriatric oncology, Aug 8, 2026

down: Decreases glucose4.7 mmol/L to 4.0 mmol/L

down: Decreases IGF-123 nmol/L to 17.9 nmol/L

up: Increases ketonenear zero to median 1.86 mmol/L

Trialtwo cycles of a 4-day FMD separated by 3 weeks of regular diet9 peopleHealthy volunteersNutrients, Aug 3, 2026

down: Decreases left ventricular massmean difference, -5.47 g

up: Improves early-to-late peak filling ratiomean difference, 0.27

up: Improves mitral annular early peak velocitymean difference, 0.84 cm/sec

Randomized trial6 months82 peopleBothmean age, 62.9 years ± 8.5Older adults; in individuals with type 2 diabetesRadiology. Cardiothoracic imaging, Jul 30, 2026

no change: Has no effect on working memory

no change: Has no effect on attentional control

down: Decreases body mass index

Randomized trial4 weeks23 peopleWomenadultActa psychologica, Jul 28, 2026

down: Decreases body weightMD = -2.32 kg, 95% CI: -2.99 to -1.65

down: Decreases HbA1cMD = -0.55, 95% CI: -0.77 to -0.33

down: Decreases body weight

Review of trials805 people pooledOverweight or obese adults with type 2 diabetesFrontiers in nutrition, Jul 15, 2026

up: Increases high molecular weight adiponectin

down: Decreases ceramide

Randomized trial2-year period191 peopleBothaged 21 to 50 yearsHealthy, non-obese (BMI 22–27.9 kg/m2) men and premenopausal womenNature communications, Jul 9, 2026

up: Improves long-term memory

up: Increases DTI-ALPS index

down: Decreases gBOLD/CSF coupling

Trial1 monthMenIn metabolic syndromeJournal of Alzheimer's disease : JAD, Jul 8, 2026

no change: Has no effect on hepatic fat fractionmean difference -0.4%, 95% CI -2.3 to 1.5

down: Decreases hepatic fat fractionmean change -1.2%, 95% CI -2.2 to -0.2

Randomized trial12 weeks197 people98 womenaged 30–60 yearsWhite European adults from Spain with overweight or obesity and abdominal obesityJHEP reports : innovation in hepatology, Jul 7, 2026

no change: Has no effect on resting energy expenditure

no change: Has no effect on resting energy expenditure

Randomized trial3 months102 peopleBoth18 to 65 yearsMidlife adults; Patient cohortsNutrients, Jun 24, 2026

down: Decreases HbA1c

down: Decreases nighttime glucose

up: Improves time in range

Treated cohort3 months3 people43, 54, 61 yearsAdults with T2DMFrontiers in clinical diabetes and healthcare, Jun 23, 2026

down: Decreases body weight

Randomized trial10 days97 peoplewomenmean age 60.6 ± 6.87 yearsCaucasian postmenopausal women with obesity and knee osteoarthritismedRxiv, Jun 11, 2026

down: Decreases fat mass

up: Increases fat-free mass

Randomized trial12-week dietary intervention30 peopleadult femalesbetween 18 and 65 years of ageAdult femalesNutrients, Jun 5, 2026

down: Decreases HbA1c-0.46% [95% CI, -0.80, -0.12], P = 0.01

no change: Has no effect on body weight-2.19% [95% CI, -5.70, -1.31]

no change: Has no effect on body weight-0.47% [95% CI, -4.72, 3.78]

Randomized trial6 months32 peopleBoth41 [15] yearsMidlife adults; Patient cohortsADA Scientific Sessions 2026 abstract, Jun 5, 2026

down: Decreases diabetes medication burden67%

up: Increases type 2 diabetes remission14%

Randomized trial12 months57 peoplePatient cohortsADA Scientific Sessions 2026 abstract, Jun 5, 2026

down: Decreases body weight

down: Decreases fat mass

down: Decreases fat-free mass

Review of trials1,833 people pooled<30 yearsGeneral population; Midlife adultsNutrients, Jun 3, 2026

down: Decreases adaptive thermogenesis−13 ± 160 kcal vs. −83 ± 150 kcal, p = 0.038

no change: Has no effect on resting metabolic rateβ_group = 47 ± 32 kcal/day

down: Decreases hunger−14 cm*min vs. 24 cm*min, p = 0.048

Randomized trial7 d100 peoplemean age ~33 yearsAdults with severe obesityJournal of human nutrition and dietetics : the official journal of the British Dietetic Association, Jun 1, 2026

down: Decreases body weight−1.8 kg vs 0.05 kg

no change: Has no effect on acute kidney injury incidence

down: Decreases inflammatory factors

Trialseven days before donation12 people50% male in the control group and 60% male in the CR groupmean age 52 yearsPatients scheduled for living kidney transplantationnpj aging, May 28, 2026

down: Decreases body weight

down: Decreases energy intake−235 kcal; 95% CI: −356, −114

up: Improves diet quality

Randomized trial12 months220 peopleBoth38.1±7.2 years oldHealthy individuals with normal weight or overweightCritical reviews in food science and nutrition, May 22, 2026

down: Decreases body weight

up: Increases dietary restraint

down: Decreases disinhibition

Randomized trial2 and 6 months209 peopleBoth58 ± 10 yearsMidlife adults; Older adults; Adults with obesityClinical nutrition (Edinburgh, Scotland), May 15, 2026